Curasight
2.04
DKK
+2 %
CURAS
Spotlight Stock Market
Medical Equipment & Services
Health Care
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreLatest research
Latest analysis report
Released: 2025-05-07
Financial calendar
Interim report Q2'25
Interim report Q3'25
BioStock: Curasight’s CEO: “We will deliver key milestones in the next 12 months”
Curasight: The exercise period commences for warrants of series TO3 on 4 June 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue
Curasight: Completed registration of rights issue
Resolutions of the Annual General Meeting 2025 of Curasight A/S
Curasight announces outcome in rights issue
Subscription of new shares in the Right Issue 2025 exercised by Curasight management
Curasight: Notice of Annual General Meeting 2025
Last day of the subscription period in Curasight's rights issue of shares
Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer
